nature portfolio

Corresponding author(s):	Daichao Wu
Last updated by author(s):	Sep 7, 2025

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics					
For all statistical ar	nalyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a Confirmed					
The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
X	atistical test(s) used AND whether they are one- or two-sided mmon tests should be described solely by name; describe more complex techniques in the Methods section.				
A descript	tion of all covariates tested				
A descript	description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
X	ypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted ses as exact values whenever suitable.				
For Bayes	ian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
For hierar	chical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
Estimates	of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated				
ı	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software an	d code				
Policy information	about <u>availability of computer code</u>				
Data collection	XDS, BiaCore 8k				
Data analysis	HKL3000, CCP4, Phenix, COOT				
	g custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.				
Data					
All manuscripts m	about <u>availability of data</u> sust include a <u>data availability statement</u> . This statement should provide the following information, where applicable: s, unique identifiers, or web links for publicly available datasets				

- For clinical datasets or third party data, please ensure that the statement adheres to our policy

PDB accession codes: 9K2I, and 9WK0

Research inv	olving hui	man participants, their data, or biological material	
Policy information and sexual orientat		ith <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation), chnicity and racism</u> .	
Reporting on sex	and gender	This information has not been collected.	
Reporting on race other socially rele groupings		This information has not been collected.	
Population chara	cteristics	This information has not been collected.	
Recruitment		This information has not been collected.	
Ethics oversight		This information has not been collected.	
Note that full informa	ation on the appro	oval of the study protocol must also be provided in the manuscript.	
Field-spe	ecific re	porting	
· · · · · ·		the best fit for your research. If you are not sure, read the appropriate sections before making your selection.	
X Life sciences		ehavioural & social sciences	
		all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>	
Life scier	nces stu	ıdy design	
All studies must dis	close on these	points even when the disclosure is negative.	
Sample size	We determined	two structures of Rac1P29S-HLA-A2 and TCR5934-Rac1P29S-HLA-A2.	
Data exclusions	We determined	two structures of Rac1P29S-HLA-A2 and TCR5934-Rac1P29S-HLA-A2.	
Replication	We repeated three times.		
Randomization	We determined two structures of Rac1P29S-HLA-A2 and TCR5934-Rac1P29S-HLA-A2.		
Blinding	We determined two structures of Rac1P29S-HLA-A2 and TCR5934-Rac1P29S-HLA-A2.		
Reporting for specific materials, systems and methods			
·		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
Materials & exp			
n/a Involved in the study n/a Involved in the study ChIP-seq		n/a Involved in the study ChIP-seq	
		Flow cytometry	
Palaeontology and archaeology MRI-based neuroimaging			
Animals and other organisms			
Clinical data			
Dual use research of concern Dual use research of concern			

Plants

Seed stocks	not relavant
Novel plant genotypes	not relavant
Authentication	not relavant